139 related articles for article (PubMed ID: 35687769)
1. Clinical relevance of receptor conversion in metastatic breast cancer: Case report.
Silva DJ; Miranda G; Mesquita A
Medicine (Baltimore); 2022 Jun; 101(23):e29136. PubMed ID: 35687769
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
3. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
4. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
5. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Robson M; Ruddy KJ; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Li W; Tung N; Armstrong A; Delaloge S; Bannister W; Goessl C; Degboe A; Hettle R; Conte P
Eur J Cancer; 2019 Oct; 120():20-30. PubMed ID: 31446213
[TBL] [Abstract][Full Text] [Related]
8. A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
Mahtani R; Holmes FA; Badve S; Caldera H; Coleman R; Mamounas E; Kalinsky K; Kittaneh M; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Vogel C;
Clin Breast Cancer; 2020 Jun; 20(3):e251-e260. PubMed ID: 32139271
[TBL] [Abstract][Full Text] [Related]
9. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
10. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.
Ciruelos E; Pérez-García JM; Gavilá J; Rodríguez A; de la Haba-Rodriguez J
Clin Drug Investig; 2019 Jul; 39(7):595-606. PubMed ID: 31054086
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
13. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
[TBL] [Abstract][Full Text] [Related]
14. [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
Yabe N; Murai S; Shimizu H; Kitasato K; Yoshikawa T; Oto I; Nakadai J; Jinno H; Kitagawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2396-8. PubMed ID: 24394124
[TBL] [Abstract][Full Text] [Related]
15. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
16. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
[TBL] [Abstract][Full Text] [Related]
18. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
